Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Leuk Lymphoma. 2024 Jul;65(7):873-881. doi: 10.1080/10428194.2024.2333448. Epub 2024 Apr 9.
Chromosomal aberrations are a common feature of cancer and can fuel cancer progression and treatment resistance. In chronic lymphocytic leukemia (CLL), the presence of multiple chromosomal aberrations is commonly referred to as "genomic complexity" or "complex karyotype"- (CKT). In the context of chemo- and chemoimmunotherapy, genomic complexity is associated with poor response to treatment and short survival, while some targeted therapies are able to mitigate its adverse prognostic impact. This article reviews currently available data and literature on the role of genomic complexity in CLL. The currently established tools to measure genomic complexity in patients with CLL are summarized and their strengths and weaknesses for routine diagnostics are evaluated. Moreover, possible definitions of CKT as an indicator for genomic complexity are discussed. Finally, data on the impact of CKT on clinical outcomes of patients with CLL are reviewed and the implications for patient stratification are presented.
染色体异常是癌症的一个常见特征，它可以促进癌症的进展和治疗耐药性。在慢性淋巴细胞白血病（CLL）中，存在多种染色体异常通常被称为“基因组复杂性”或“复杂核型”（CKT）。在化疗和化疗免疫治疗的背景下，基因组复杂性与治疗反应不良和生存时间短有关，而一些靶向治疗能够减轻其不良预后影响。本文综述了目前关于 CLL 中基因组复杂性作用的可用数据和文献。总结了目前用于评估 CLL 患者基因组复杂性的工具，并评估了它们在常规诊断中的优缺点。此外，还讨论了将 CKT 作为基因组复杂性指标的可能定义。最后，回顾了 CKT 对 CLL 患者临床结局的影响，并提出了患者分层的意义。
Zotero 插件